All Stories

  1. Efficacy and Safety of Omaveloxolone in Friedreich Ataxia: Real‐World Data from an Advanced Disease Cohort
  2. Target engagement and efficacy in disease-modifying trials of synuclein-related disorders
  3. Digital Motor Profiling in Parkinson’s Disease: Long-Term Monitoring Through Wearable Sensors
  4. Daily regulation of glucocerebrosidase activity and impact of fixed-time rotarod training in a mouse model of Gba1-associated Parkinson's disease
  5. Timing of Deep Brain Stimulation and Cognitive Trajectories in GBA1 ‐Associated Parkinson's Disease
  6. The neurologist of 2050: Rethinking the role in movement disorders in a technologically transformed society
  7. Levodopa-induced dyskinesia is associated with worse gait and balance in Parkinson’s disease
  8. L-Dopa/Carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-life mobility insights from wearable sensors
  9. Treatment stability comparison among different ADD-ON therapies in fluctuating Parkinson’s disease patients: the role of clinical and demographic factors
  10. Multicenter validation of the Italian Pain in Dystonia Scale in idiopathic adult-onset cervical dystonia
  11. The Pain in Dystonia Scale (PIDS)—Validation in Craniofacial and Upper Limb Dystonia
  12. From RGB-D to RGB-Only: Reliability and Clinical Relevance of Markerless Skeletal Tracking for Postural Assessment in Parkinson’s Disease
  13. Placebo Responses in Trials of Functional Neurologic Disorders
  14. The interplay between GBA1 status and age of onset on cognitive, motor and non-motor outcomes in Parkinson’s disease: multicenter cross-sectional study
  15. A multi-level annotated sensor dataset of gait freezing manifestations and severity in Parkinson’s disease
  16. Unraveling gait and balance impairment in cervical dystonia: associated features, functional implications, and the effect of botulinum toxin
  17. Is segmental/multifocal onset a distinct presentation of idiopathic adult-onset dystonia?
  18. Profiling Postural Instability in Parkinson’s disease: Multi-Parametric Phenotyping and Clinical Correlates from Markerless RGB-D Tracking
  19. Long-Term Motor and Cognitive Outcome of Deep Brain Stimulation in Patients With Parkinson Disease With a GBA1 Pathogenic Variant
  20. Early Detection of Dysphagia Signs in Parkinson’s Disease: An Artificial Intelligence-Based Approach Using Non-Invasive Sensors
  21. GBA1 status and sex impact on depression severity and progression in Parkinson’s Disease
  22. Clinical Algorithm‐Guided Approach to Botulinum Toxin Type A Treatment for Axial Postural Abnormalities in Parkinson's Disease
  23. Unraveling the role of GBA1 genotype in axial signs response to subthalamic deep brain stimulation
  24. Predictors of cognitive performance in idiopathic adult-onset dystonia
  25. The Complex Pathway of Conventional Investigations before the Diagnosis of Functional Motor Disorders
  26. Identifying Poor Responders to STN DBS in Parkinson Disease: The Role of Rapid Disease Progression in the First Year in Optimal Responders to Levodopa
  27. Nonmotor fluctuations in Parkinson’s disease: impact on caregiving and quality of life
  28. The Influence of Genetics in the Early Development of Axial Postural Abnormalities in Parkinson's Disease
  29. Parkinsonism-hyperpyrexia syndrome due to gastroparesis treated with subcutaneous foslevodopa: a case report
  30. The relationship between occupation and specific forms of idiopathic adult-onset dystonia
  31. Clinical MRI to predict motor and non-motor effects of deep brain stimulation in Parkinson disease
  32. Editorial: Digital biomarkers in movement disorders
  33. Theta‐Gamma Subthalamic Stimulation for Verbal Fluency in Parkinson's Disease: A Randomized, Crossover Trial
  34. Reply: “Human Pose Estimation Is Approximate: Limitations and Considerations for its Use in Clinical Trials”
  35. Advances in diagnosis, classification, and management of pain in Parkinson's disease
  36. Freezing of gait detection: The effect of sensor type, position, activities, datasets, and machine learning model
  37. Dynamic Video Assessment of Axial Postural Abnormalities in Parkinson's Disease: A Pilot Study
  38. Siponimod Modulates Functional Brain Connectivity in Patients with Transitional Multiple Sclerosis
  39. Long-term motor and cognitive outcome of Deep Brain Stimulation in GBA-PD: the Italian PARKNET study
  40. Expanded and independent validation of the NoMoFA scale for Parkinson’s disease: the Italian version
  41. First byte syndrome successfully treated with parotid gland botulinum toxin injection
  42. Behind the scenes: exploring neurological journal editors’ work habits, decisions, and potential sources of conflict of interest
  43. Subthalamic and nigral stimulation for freezing of gait in Parkinson's disease: Randomized pilot trial
  44. Unraveling the stride: exploring the influence of neurogenic orthostatic hypotension on gait and balance in Parkinson’s disease
  45. NoMoFa as a new tool to evaluate the impact of deep brain stimulation on non-motor fluctuations: A new perspective
  46. Multidisciplinary care use in neurodegenerative complex diseases: The example of progressive supranuclear palsy and advanced Parkinson's disease in real-life
  47. Effects of Continuous Dopaminergic Stimulation on Parkinson’s Disease Gait: A Longitudinal Prospective Study with Levodopa Intestinal Gel Infusion
  48. Incidence and predictors of postural abnormalities in Parkinson’s disease: a PPMI cohort study
  49. Neurological symptoms in adults with Gaucher disease: a systematic review
  50. Botulinum Toxin for Axial Postural Abnormalities in Parkinson’s Disease: A Systematic Review
  51. CACNA1A variant associated with generalized dystonia
  52. Unveiling the Unpredictable in Parkinson’s Disease: Sensor-Based Monitoring of Dyskinesias and Freezing of Gait in Daily Life
  53. Subthalamic and Nigral Stimulation for Freezing of Gait in Parkinson disease: randomized pilot trial
  54. Effects of dopaminergic therapy on sleep quality in fluctuating Parkinson’s disease patients
  55. Treatment of axial postural abnormalities in parkinsonism disorders: A systematic review of pharmacological, rehabilitative and surgical interventions
  56. Does sex influence the natural history of idiopathic adult-onset dystonia?
  57. (Re)configuration of digital health records to optimize diagnosis and therapy
  58. Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations
  59. Are patients with GBA–Parkinson disease good candidates for deep brain stimulation? A longitudinal multicentric study on a large Italian cohort
  60. Axial symptoms as main predictors of short-term subthalamic stimulation outcome in Parkinson's disease
  61. Longitudinal Assessment of Botulinum Toxin Treatment for Lateral Trunk Flexion and Pisa Syndrome in Parkinson’s Disease: Real-life, Long-Term Study
  62. Predictors and Pathophysiology of Axial Postural Abnormalities in Parkinsonism: A Scoping Review
  63. Pregnancy, fertile life factors, and associated clinical course in PRKN early-onset Parkinson’s disease
  64. Filling the Gap in Assessing Pain in Dystonia
  65. Deep Brain Stimulation Outcomes in Parkinson's Disease Patients with Cognitive Impairment: Implications and Considerations
  66. Axial Postural Abnormalities in Parkinsonism: Gaps in Predictors, Pathophysiology, and Management
  67. Should we offer deep brain stimulation to Parkinson’s disease patients with GBA mutations?
  68. 15-Year Subthalamic Deep Brain Stimulation outcome in a Parkinson’s disease patient with Parkin gene mutation: a case report
  69. The impact of dysphagia in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel
  70. Camera- and Viewpoint-Agnostic Evaluation of Axial Postural Abnormalities in People with Parkinson’s Disease through Augmented Human Pose Estimation
  71. Assessment of Axial Postural Abnormalities in Parkinsonism: Automatic Picture Analysis Software
  72. Gait and axial postural abnormalities correlations in Parkinson's disease: A multicenter quantitative study
  73. Visuospatial Deficits are associated with Pisa Syndrome and not Camptocormia in Parkinson's disease
  74. How resistant are levodopa‐resistant axial symptoms? Response of freezing, posture, and voice to increasing levodopa intestinal infusion rates in Parkinson disease
  75. Efficacy of rituximab in anti‐myelin‐associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow‐up
  76. Burden of caregiving for cardiovascular dysautonomia in Parkinson’s disease
  77. Biomechanical assessment of botulinum toxin effects in Pisa syndrome disease
  78. SARS-CoV-2 vaccination, Parkinson’s disease, and other movement disorders: case series and short literature review
  79. Task force consensus on nosology and Cut‐Off values for axial postural abnormalities in parkinsonism
  80. Postural abnormalities in Asian and Caucasian Parkinson's disease patients: A multicenter study
  81. Deep brain stimulation for atypical parkinsonism: A systematic review on efficacy and safety
  82. Time to onset and duration of botulinum toxin efficacy in movement disorders
  83. Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease
  84. Editorial: Advances in Functional Neurosurgery
  85. Standardized Biomechanical Investigation of Posture and Gait in Pisa Syndrome Disease
  86. Association between sleep disorders and cognitive dysfunctions in advanced Parkinson's disease
  87. Botulinum toxin injection in longissimus and iliocostalis muscles for treating pisa syndrome: Short- and long-term effect
  88. Cohort study of neurological comorbidities and COVID-19-related case fatality
  89. Efficacy of amantadine in patients hospitalized with COVID-19: Study protocol of a randomized, double-blind, placebo-controlled trial
  90. Freezing of gait in subthalamic deep brain stimulation for Parkinsons disease: A pilot study on safety and tolerability of variable versus low frequencies stimulation
  91. The prognostic value of G325R GBA mutation on the long-term deep brain stimulation outcome in Parkinson's disease
  92. Ventral tegmental area disconnection contributes two years early to correctly classify patients converted to Alzheimer’s disease: Implications for treatment
  93. Early reversible leukoencephalopathy and unilateral sixth cranial nerve palsy in mild COVID-19 infection
  94. G325R GBA mutation in Parkinson's disease: Disease course and long-term DBS outcome
  95. Neurological comorbidities and COVID-19-related case fatality: A cohort study
  96. Ventral Tegmental Area Disconnection Contributes Two Years Early to Correctly Classify Patients Converted to Alzheimer’s Disease: Implications for Treatment
  97. Association between sleep disorders and cognitive dysfunctions in non-demented patients with advanced Parkinson’s disease
  98. Effect of Deep Brain Stimulation Frequency on Gait Symmetry, Smoothness and Variability using IMU
  99. Deep brain stimulation fine-tuning in Parkinson's disease: Short pulse width effect on speech
  100. Anxiety, depression, and worries in advanced Parkinson disease during COVID-19 pandemic
  101. Comment on: “Point of view: Wearable systems for at-home monitoring of motor complications in Parkinson's disease should deliver clinically actionable information”
  102. Deep brain stimulation outcomes in the malignant end of Parkinson's disease spectrum
  103. Motor and non-motor outcomes of subthalamic deep brain stimulation in a case of juvenile PARK-PINK1
  104. Focal seizures with impaired awareness as long-term neurological complication of COVID-19: a case report
  105. COVID-19 and Parkinson’s Disease: What Do We Know So Far?
  106. Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials
  107. Safety and efficacy of tolcapone in Parkinson’s disease: systematic review
  108. Speech Impairment in Parkinson’s Disease: Acoustic Analysis of Unvoiced Consonants in Italian Native Speakers
  109. Digital work engagement among Italian neurologists
  110. Low frequency subthalamic stimulation and event-related potentials in Parkinson disease
  111. Deep Brain Stimulation Selection Criteria for Parkinson’s Disease: Time to Go beyond CAPSIT-PD
  112. COVID-19 in Parkinson's disease: Report on prevalence and outcome
  113. Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail
  114. Levodopa/Carbidopa Intestinal Gel Long‐Term Outcome in Parkinson's Disease: Focus on Dyskinesia
  115. A new index to assess turning quality and postural stability in patients with Parkinson's disease
  116. Neurological comorbidity and severity of COVID-19
  117. Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential
  118. Detection of Freezing of Gait in People with Parkinson’s Disease using Smartphones
  119. Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications
  120. Smartphone-Based Evaluation of Postural Stability in Parkinson’s Disease
  121. Tuning Deep Brain Stimulation related depression by frequency modulation: a case report
  122. Onset of Covid-19 with impaired consciousness and ataxia: a case report
  123. Should We Consider Deep Brain Stimulation Discontinuation in Late‐Stage Parkinson's Disease?
  124. Changing the Side of Pisa Syndrome: A Case of Over‐Recovery with Botulinum Toxin
  125. Does the Degree of Trunk Bending Predict Patient Disability, Motor Impairment, Falls, and Back Pain in Parkinson's Disease?
  126. Video analysis of long-term effects of levodopa-carbidopa intestinal gel on gait and posture in advanced Parkinson’s disease
  127. Differential response to pallidal deep brain stimulation among monogenic dystonias: systematic review and meta-analysis
  128. Smartphone-Based Estimation of Leg Agility in People With Parkinson's Disease
  129. Validity of the wall goniometer as a screening tool to detect postural abnormalities in Parkinson's disease
  130. Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors
  131. Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study
  132. Home monitoring of motor fluctuations in Parkinson’s disease patients
  133. Telemedicine in Neurological Disorders: Opportunities and Challenges
  134. Complex therapies for advanced Parkinson’s disease: what is the role of doctor-patient communication?
  135. Levodopa-Induced Dyskinesias and Dyskinesias-Reduced-Self-Awareness in Parkinson’s Disease: A Neurocognitive Approach
  136. Pisa Syndrome in Parkinson's Disease Is Associated With Specific Cognitive Alterations
  137. Long‐term effect of levodopa‐carbidopa intestinal gel on axial signs in Parkinson’s disease
  138. Botulinum toxin for Pisa syndrome: An MRI-, ultrasound- and electromyography-guided pilot study
  139. Effect of subthalamic deep brain stimulation on posture in Parkinson's disease: A blind computerized analysis
  140. Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study
  141. Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease
  142. Levodopa‐Induced Neuropathy: A Systematic Review
  143. Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution
  144. Cardiovascular autonomic neuropathy and falls in Parkinson disease: a prospective cohort study
  145. Dopaminergic dose adjustment and negative affective symptoms after deep brain stimulation
  146. Subthalamic deep brain stimulation and levodopa in Parkinson’s disease: a meta-analysis of combined effects
  147. Deep brain stimulation in uncommon tremor disorders: indications, targets, and programming
  148. Effects of intestinal Levodopa infusion on freezing of gait in Parkinson disease
  149. Orthostatic hypotension in Parkinson disease: Impact on health care utilization
  150. Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases
  151. Subthalamic deep brain stimulation and trunk posture in Parkinson's disease
  152. To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy
  153. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis
  154. Natalizumab in Multiple Sclerosis: Long-Term Management
  155. Prevalence and burden of dysautonomia in advanced Parkinson's disease
  156. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab
  157. The still under-investigated role of cognitive deficits in PML diagnosis
  158. Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry
  159. Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
  160. Parkinsonism–hyperpyrexia syndrome and deep brain stimulation
  161. Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia
  162. Earlier versus later subthalamic deep brain stimulation in Parkinson's disease
  163. Subthalamic deep brain stimulation: clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients
  164. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience
  165. Medical therapy and subthalamic deep brain stimulation in advanced Parkinson's disease: a different long-term outcome?
  166. Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients
  167. 80 Hz versus 130 Hz subthalamic nucleus deep brain stimulation: Effects on involuntary movements
  168. Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study
  169. Transient effects of 80 Hz stimulation on gait in STN DBS treated PD patients: A 15 months follow-up study
  170. Subthalamic nucleus deep brain stimulation outcome in young onset Parkinson's disease: a role for age at disease onset?
  171. Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson's disease
  172. Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients